Smurf1-IN-A01

Smurf1-IN-A01 is a Smurf1 inhibitor. Smurf1-IN-A01 has anticancer activity and can be used for the research of osteoporosis and age-related macular degeneration[1][2][3][4].

Product Specifications

CAS Number

[1007647-73-5]

Product Name Alternative

A01

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

Estrogen Receptor/ERR; HSP; Interleukin Related; MyD88; NF-κB

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; Vitamin D Related/Nuclear Receptor

Field of Research

Others; Cancer

Assay Protocol

https://www.medchemexpress.com/smurf1-in-a01.html

Purity

99.81

Solubility

DMSO : 62.5 mg/mL (ultrasonic)

Smiles

O=S(C1=CC(C(F)(F)F)=C(Cl)C=C1)(N2CCN(C(C3=CC=C(N4C(C)=CC=N4)C=C3)=O)CC2)=O

Molecular Formula

C22H20ClF3N4O3S

Molecular Weight

512.93

Precautions

H315, H319, H335

References & Citations

[1]Cao Y, et al. Selective small molecule compounds increase BMP-2 responsiveness by inhibiting Smurf1-mediated Smad1/5 degradation. Sci Rep. 2014 May 14;4:4965.|[2]Li F, et al. C-type lectin receptor 2d forms homodimers and heterodimers with TLR2 to negatively regulate IRF5-mediated antifungal immunity [J]. Nature Communications, 2023, 14 (1) : 6718.|[3]Qu M, et al. HSP90β chaperoning SMURF1-mediated LATS proteasomal degradation in the regulation of bone formation [J]. Cellular Signalling, 2023, 102: 110523.|[4]Yang H, et al. SMURF1 facilitates estrogen receptor ɑ signaling in breast cancer cells [J]. Journal of experimental & clinical cancer research, 2018, 37 (1) : 1-12.|[5]Li D, et al. Smurf1: A possible therapeutic target in dry age-related macular degeneration [J]. Experimental Eye Research, 2023, 233: 109549.